Share This Page
Suppliers and packagers for generic pharmaceutical drug: LOXAPINE SUCCINATE
✉ Email this page to a colleague
LOXAPINE SUCCINATE
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Elite Labs Inc | LOXAPINE SUCCINATE | loxapine succinate | CAPSULE;ORAL | 076868 | ANDA | Elite Laboratories, Inc. | 64850-890-01 | 100 CAPSULE in 1 BOTTLE (64850-890-01) | 2020-01-27 |
| Elite Labs Inc | LOXAPINE SUCCINATE | loxapine succinate | CAPSULE;ORAL | 076868 | ANDA | Elite Laboratories, Inc. | 64850-891-01 | 100 CAPSULE in 1 BOTTLE (64850-891-01) | 2020-01-27 |
| Elite Labs Inc | LOXAPINE SUCCINATE | loxapine succinate | CAPSULE;ORAL | 076868 | ANDA | Elite Laboratories, Inc. | 64850-892-01 | 100 CAPSULE in 1 BOTTLE (64850-892-01) | 2020-01-27 |
| Elite Labs Inc | LOXAPINE SUCCINATE | loxapine succinate | CAPSULE;ORAL | 076868 | ANDA | Elite Laboratories, Inc. | 64850-893-01 | 100 CAPSULE in 1 BOTTLE (64850-893-01) | 2020-01-27 |
| Elite Labs Inc | LOXAPINE SUCCINATE | loxapine succinate | CAPSULE;ORAL | 076868 | ANDA | REMEDYREPACK INC. | 70518-4311-0 | 30 CAPSULE in 1 BLISTER PACK (70518-4311-0) | 2025-03-17 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Loxapine Succinate
Introduction
Loxapine succinate, a typical antipsychotic medication primarily used to manage schizophrenia and agitation, is a significant component within the psychiatric pharmacotherapy landscape. Its efficacy, safety profile, and regulatory status make its supply chain critical for pharmaceutical manufacturers and healthcare providers worldwide. This article explores the primary suppliers of loxapine succinate, examining manufacturing sources, regional dynamics, regulatory considerations, and market trends vital for industry decision-makers.
Overview of Loxapine Succinate
Loxapine succinate is a first-generation antipsychotic belonging to the dibenzoxazepine class. It functions as a dopamine antagonist and has sedative properties when administered via inhalation or orally. Its synthesis involves complex chemical processes requiring specialized intermediaries and stringent quality control. The global demand for loxapine succinate remains steady, driven by clinical applications in schizophrenia treatment and acute agitation management, particularly in hospital settings.
Major Suppliers of Loxapine Succinate
1. Teva Pharmaceutical Industries Ltd.
Teva is a leading global generics manufacturer headquartered in Israel, with extensive product lines including neuropsychiatric medications. The company manufactures loxapine succinate as part of its portfolio of antipsychotics. Teva's manufacturing facilities in Israel and Europe adhere to current Good Manufacturing Practices (cGMP), ensuring product quality and regulatory compliance across markets.
2. Mylan NV (now part of Viatris Inc.)
Mylan, acquired by Viatris in 2020, has historically supplied generic loxapine products worldwide. The company operates several manufacturing sites, notably in the United States and Europe, providing loxapine succinate in various dosage forms. Viatris continues to leverage Mylan’s manufacturing expertise to fulfill global demand, emphasizing supply stability amid increasing pharmaceutical scrutiny.
3. Par Pharmaceutical (Part of Endo Pharmaceuticals)
Par Pharmaceutical, a key US-based generic manufacturer, supplies loxapine succinate mainly within North America. Its manufacturing facilities in the US focus on high-quality production standards, contributing to the supply chain stability for mental health therapies in North American markets.
4. Zydus Cadila Healthcare Ltd.
Zydus Cadila, an Indian pharmaceutical giant, produces loxapine succinate for regional and potentially export markets. Its manufacturing units in India are cGMP-certified, and the company has been expanding its portfolio of neuropsychiatric therapies to meet rising demand in Asia and emerging markets.
5. Other Regional and Generic Manufacturers
Additional regional suppliers include Sun Pharmaceutical Industries (India), Torrent Pharmaceuticals, and Dr. Reddy's Laboratories, which manufacture loxapine succinate for local markets and export to neighboring regions. These companies often compete on price and supply reliability, catering to developing country markets.
Manufacturing and Supply Chain Considerations
The production of loxapine succinate involves complex chemical syntheses requiring specialty intermediates, strict process control, and rigorous quality assurance. Suppliers must navigate regulatory landscapes, certification requirements, and regional restrictions to maintain a stable supply chain.
Most key manufacturers hold or seek approvals from regulatory agencies, including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other national bodies. Their manufacturing facilities typically operate under cGMP standards, ensuring consistent product quality.
Supply disruptions may occur due to raw material shortages, regulatory hurdles, or manufacturing challenges, emphasizing the importance of diversified sourcing strategies among pharmaceutical companies relying on loxapine succinate.
Regional Market Dynamics and Regulatory Environment
United States
In the US, the Food and Drug Administration (FDA) oversees manufacturing standards for generic drugs. Suppliers such as Teva, Mylan/Viatris, and Par Pharma have established FDA-approved manufacturing sites, ensuring market access. Patent expirations and regulatory approvals have facilitated increased generic competition, often impacting pricing and supply stability.
Europe
European markets demand compliance with EMA regulations, with suppliers like Teva and Zydus Cadila holding significant market shares. The European Union's centralized drug approval systems promote uniform standards, making regional manufacturing facilities critical for consistent supply.
Emerging Markets
India and Southeast Asia are witnessing expanding procurement of loxapine succinate from local manufacturers such as Zydus and Sun Pharma. These regional suppliers benefit from lower production costs, but face challenges related to regulatory heterogeneity and supply chain logistics.
Market Trends and Future Outlook
The global psychiatric medication market is anticipated to grow steadily, driven by increasing awareness and diagnosis of mental health disorders. Consequently, the demand for antipsychotics, including loxapine succinate, is expected to rise.
The emergence of biosimilars and new generation antipsychotics may influence generic market dynamics. However, the entrenched role of first-generation antipsychotics ensures continued demand for loxapine succinate, especially in regions with cost-sensitive healthcare systems.
Manufacturers are investing in process innovation, such as continuous manufacturing and improved synthesis methods, aiming to enhance yield, reduce costs, and mitigate supply risks.
Key Challenges
- Regulatory Hurdles: Navigating complex approval processes across multiple jurisdictions can delay supply and affect market access.
- Raw Material Dependence: Sourcing specialty intermediates remains a vulnerability, especially amid global supply chain disruptions.
- Pricing Pressures: Intense generic competition constrains margins but incentivizes manufacturers to optimize production efficiencies.
- Quality Assurance: Maintaining consistent, high-quality drug specifications is vital for regulatory compliance and patient safety.
Conclusion
The supply chain for loxapine succinate hinges on a limited yet robust list of global and regional manufacturers. Major players such as Teva, Viatris (formerly Mylan), Zydus Cadila, and Par Pharmaceuticals dominate the landscape, leveraging established manufacturing capabilities and regulatory compliance. Growing healthcare demand, combined with technological advancements and regional market expansion, indicates a sustained need for reliable suppliers. Procurement strategies should emphasize supplier diversification, quality assurance, and regulatory alignment to mitigate risks amid a dynamic pharmaceutical landscape.
Key Takeaways
- The leading suppliers for loxapine succinate include Teva, Viatris (formerly Mylan), Zydus Cadila, and Par Pharmaceutical.
- Manufacturing complexities necessitate strict quality control and compliance with global regulatory standards.
- Regional variations influence supplier landscape, with emerging markets increasingly autonomous through homegrown production.
- Market growth driven by rising mental health awareness sustains demand despite pressures from newer antipsychotics.
- Diversification of supply sources and investment in process innovations mitigate risks of disruptions and supply shortages.
FAQs
1. Who are the primary global manufacturers of loxapine succinate?
The primary global manufacturers include Teva Pharmaceutical Industries, Viatris (formerly Mylan), Zydus Cadila, and Par Pharmaceutical.
2. What regulatory considerations impact loxapine succinate suppliers?
Suppliers must comply with cGMP standards, FDA or EMA approvals, and regional regulatory requirements, which influence manufacturing, distribution, and market access.
3. Are there regional differences in supplier availability for loxapine succinate?
Yes. North America and Europe have well-established suppliers such as Teva and Mylan, while India-based companies like Zydus and Sun Pharma serve emerging markets.
4. What are the major challenges facing suppliers of loxapine succinate?
Manufacturing complexity, raw material availability, regulatory hurdles, pricing pressures, and supply chain disruptions are key challenges.
5. What is the outlook for the future supplier landscape of loxapine succinate?
The landscape is likely to remain stable with dominant players maintaining market share, though increased regional manufacturing and process innovations may diversify supply sources over time.
Sources:
- [1] Teva Pharmaceutical Industries, Corporate Website, 2023.
- [2] Viatris Inc., Annual Report, 2022.
- [3] Zydus Cadila Healthcare Ltd., Company Profile, 2023.
- [4] U.S. Food and Drug Administration (FDA), Approved Drug Products, 2023.
- [5] European Medicines Agency (EMA), Approved Medicinal Products, 2023.
More… ↓
